Macrophage homeostasis implies proper function for its specific tissue, environment and challenge

Reprogramming imbalanced macrophage populations can lead to disease resolution
Macrophages’ function is a sum of their designation, the local environment in which they reside, and the type of situation or pathogen to which they are exposed. Reprogrammed out of their homeostatic state, macrophages contribute to the pathophysiology of multiple diseases including cancer and various inflammatory disorders.

Macrophage
Macrophage

Allocetra™ immune rebalancing

Allocetra™ is an innovative immunotherapy that is being developed to reprogram macrophages,
which were negatively reprogrammed by certain diseases out of their homeostatic state.

Download investor presentation

We reset macrophages into their homeostatic state

Non-homeostatic macrophages
Allocetra™ infusion
Macrophage feeding
Macrophages reset
Homeostasis restored

Pipeline of reprogrammable macrophage-modulated indications

Indication Global
Market Size
Pre
Clinical
Phase
Ib
Phase
IIb
EU Conditional
Marketing Approval
Post EU
Marketing
US Phase 3
Organ failure associated with Sepsis $33B   Completed Phase IIb Initiation Q1 2021    
             
ARDS associated with severe/critical COVID-19 / Non-COVID-19 ARDS $1B (COVID)
$15B (ARDS)
  Completed
COVID-19
Phase II Ongoing
COVID-19
   
             
Solid tumors in combination with immune checkpoints $4B   Q3 2021      
             
View full pipeline

Our Mission

Our mission is to establish new equilibriums that solve complex diseases.

As a clinical-stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, Sepsis, COVID-19 and other indications.

Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.

About us

Strong leadership,
inspired by great science and a sense of mission

Our management, clinical advisors, personnel, and affiliates have extensive knowledge in the research and development of therapies based on macrophage reprogramming.

Meet the team

Find out more

14 Einstein St. Nes-Ziona 7403618, Israel
T +972.8.6623301  |  F +972.8.6312981
info@enlivexpharm.com